|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
1,518,000 |
Market
Cap: |
10.26(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$5.2 - $18.63 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Kala Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for diseases of the eye. Co.'s two marketed products are EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25%, for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Co. is also progressing its pipeline of proprietary programs targeted to address front and back of the eye diseases, including KPI-287 and glucocorticoid receptor modulators.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
11,400 |
11,400 |
3,865,837 |
Total Sell Value |
$0 |
$76,777 |
$76,777 |
$1,938,481 |
Total People Sold |
0 |
6 |
6 |
7 |
Total Sell Transactions |
0 |
6 |
6 |
15 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bazemore Todd |
Chief Operating Officer |
|
2020-03-16 |
4 |
B |
$5.75 |
$57,500 |
D/D |
10,000 |
10,000 |
2.74 |
59% |
|
Grunberg Gregory |
Director |
|
2020-03-13 |
4 |
B |
$7.89 |
$19,999,998 |
I/I |
2,534,854 |
2,534,854 |
2.1 |
58% |
|
Shah Rajeev M. |
Director |
|
2020-03-13 |
4 |
B |
$7.89 |
$49,999,995 |
I/I |
6,337,135 |
10,874,613 |
2.25 |
58% |
|
Kolchinsky Peter |
Director |
|
2020-03-13 |
4 |
B |
$7.89 |
$49,999,995 |
I/I |
6,337,135 |
10,874,613 |
2.25 |
58% |
|
Rosen Howard B |
Director |
|
2019-05-30 |
4 |
B |
$5.42 |
$27,100 |
D/D |
5,000 |
8,240 |
2.39 |
- |
|
Grunberg Gregory |
Director |
|
2018-10-05 |
4 |
B |
$8.25 |
$4,999,995 |
I/I |
606,060 |
2,877,006 |
2.1 |
- |
|
Kolchinsky Peter |
Director |
|
2018-10-03 |
4 |
B |
$8.25 |
$19,999,997 |
I/I |
2,424,242 |
4,537,478 |
2.25 |
- |
|
Shah Rajeev M. |
Director |
|
2018-10-03 |
4 |
B |
$8.25 |
$19,999,997 |
I/I |
2,424,242 |
4,537,478 |
2.25 |
- |
|
Chen Hongming |
Chief Scientific Officer |
|
2018-02-28 |
4 |
OE |
$2.24 |
$22,123 |
D/D |
9,769 |
55,849 |
|
- |
|
Orbimed Capital Gp Vi Llc |
10% Owner |
|
2018-02-08 |
4 |
B |
$12.93 |
$323,250 |
I/I |
25,000 |
3,447,840 |
1.5 |
- |
|
Orbimed Capital Gp Vi Llc |
10% Owner |
|
2018-02-02 |
4 |
B |
$14.73 |
$557,383 |
I/I |
37,840 |
3,422,840 |
1.5 |
- |
|
Orbimed Capital Gp Vi Llc |
10% Owner |
|
2018-02-01 |
4 |
B |
$14.99 |
$342,372 |
I/I |
22,840 |
3,385,000 |
1.5 |
- |
|
Orbimed Capital Gp Vi Llc |
10% Owner |
|
2018-01-31 |
4 |
B |
$15.00 |
$5,091,000 |
I/I |
339,400 |
3,362,160 |
1.5 |
- |
|
Orbimed Capital Gp Vi Llc |
10% Owner |
|
2018-01-29 |
4 |
B |
$14.99 |
$749,500 |
I/I |
50,000 |
3,022,760 |
1.5 |
- |
|
Orbimed Capital Gp Vi Llc |
10% Owner |
|
2018-01-26 |
4 |
B |
$14.93 |
$339,807 |
I/I |
22,760 |
2,972,760 |
1.5 |
- |
|
Orbimed Capital Gp Vi Llc |
10% Owner |
|
2018-01-24 |
4 |
B |
$14.91 |
$963,738 |
I/I |
64,637 |
2,950,000 |
1.5 |
- |
|
Orbimed Capital Gp Vi Llc |
10% Owner |
|
2018-01-23 |
4 |
B |
$14.99 |
$65,401 |
I/I |
4,363 |
2,885,363 |
1.5 |
- |
|
Orbimed Capital Gp Vi Llc |
10% Owner |
|
2018-01-22 |
4 |
B |
$14.98 |
$1,123,500 |
I/I |
75,000 |
2,881,000 |
1.5 |
- |
|
Orbimed Capital Gp Vi Llc |
10% Owner |
|
2018-01-19 |
4 |
B |
$14.95 |
$1,120,218 |
I/I |
74,931 |
2,806,000 |
1.5 |
- |
|
Orbimed Capital Gp Vi Llc |
10% Owner |
|
2018-01-12 |
4 |
B |
$14.50 |
$556,133 |
I/I |
38,354 |
2,731,069 |
1.5 |
- |
|
Isaly Samuel D |
10% Owner |
|
2018-01-12 |
4 |
B |
$15.40 |
$438,068 |
I/I |
28,446 |
2,692,715 |
1.5 |
- |
|
Isaly Samuel D |
10% Owner |
|
2018-01-11 |
4 |
B |
$13.65 |
$569,205 |
I/I |
41,700 |
2,664,269 |
1.5 |
- |
|
Isaly Samuel D |
10% Owner |
|
2018-01-10 |
4 |
B |
$12.83 |
$2,185,437 |
I/I |
170,338 |
2,622,569 |
1.5 |
- |
|
Brazzell Kim |
Chief Medical Officer |
|
2017-08-11 |
4 |
OE |
$0.68 |
$178,039 |
D/D |
108,725 |
108,725 |
|
- |
|
Isaly Samuel D |
See Remarks |
|
2017-07-25 |
4 |
B |
$15.00 |
$4,789,995 |
I/I |
319,333 |
2,375,279 |
1.5 |
- |
|
144 Records found
|
|
Page 5 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|